Titration	NN
of	IN
non-replicating	JJ
adenovirus	NN
as	IN
a	DT
vector	NN
for	IN
transducing	VBG
active	JJ
TGF-beta1	NN
gene	NN
expression	NN
causing	VBG
inflammation	NN
and	CC
fibrogenesis	NN
in	IN
the	DT
lungs	NNS
of	IN
C57BL/6	NN
mice	NNS
.	.

Investigators	NNS
have	VBP
shown	VBN
that	IN
interstitial	JJ
pulmonary	JJ
fibrosis	NN
(	(
IPF	NN
)	)
can	MD
be	VB
induced	VBN
in	IN
rats	NNS
by	IN
overexpressing	VBG
transforming-growth-factor-beta1	NN
(	(
TGF-beta1	NN
)	)
through	IN
a	DT
replication-deficient	JJ
recombinant	JJ
adenovirus	NN
vector	NN
instilled	VBD
into	IN
the	DT
lungs	NNS
(	(
Sime	NNP
et	FW
al.	FW
1997	CD
)	)
.	.

We	PRP
have	VBP
shown	VBN
that	IN
this	DT
vector	NN
induces	VBZ
IPF	NN
in	IN
fibrogenic-resistant	JJ
tumour	NN
necrosis	NN
factor	NN
alpha-receptor	NN
knockout	NN
(	(
TNF-alphaRKO	NN
)	)
mice	NNS
(	(
Liu	NNP
et	FW
al.	FW
2001	CD
)	)
.	.

The	DT
object	NN
of	IN
our	PRP$
studies	NNS
is	VBZ
to	TO
understand	VB
how	WRB
peptide	NN
growth	NN
factors	NNS
,	,
such	JJ
as	IN
TGF-beta1	NN
,	,
mediate	VBP
interstitial	JJ
lung	NN
disease	NN
(	(
ILD	NN
)	)
.	.

To	TO
do	VB
so	RB
,	,
we	PRP
must	MD
be	VB
able	JJ
to	TO
manipulate	VB
the	DT
dose	NN
of	IN
the	DT
factor	NN
and	CC
sort	NN
out	IN
its	PRP$
effects	NNS
on	IN
multiple	JJ
other	JJ
mediators	NNS
in	IN
the	DT
lung	NN
parenchyma	NN
.	.

As	IN
a	DT
step	NN
in	IN
this	DT
complex	JJ
process	NN
,	,
in	IN
the	DT
studies	NNS
reported	VBN
here	RB
,	,
we	PRP
have	VBP
determined	VBN
the	DT
concentrations	NNS
of	IN
the	DT
recombinant	JJ
adenovirus	NN
vector	NN
carrying	VBG
the	DT
gene	NN
for	IN
porcine	NN
active	JJ
TGF-beta1	NN
(	(
AVTGFbeta1	NN
)	)
that	WDT
have	VBP
little	JJ
apparent	JJ
effect	NN
,	,
cause	VB
clear	JJ
induction	NN
of	IN
disease	NN
,	,
or	CC
severe	JJ
disease	NN
.	.

The	DT
disease	NN
largely	RB
resolves	VBZ
by	IN
28	CD
days	NNS
in	IN
all	DT
cases	NNS
,	,
thus	RB
providing	VBG
a	DT
valuable	JJ
model	NN
to	TO
understand	VB
the	DT
mechanisms	NNS
of	IN
the	DT
IPF	NN
that	WDT
is	VBZ
mediated	VBN
,	,
at	IN
least	JJS
in	IN
part	NN
,	,
by	IN
TGF-beta1	NN
.	.

The	DT
findings	NNS
here	RB
show	VBP
that	IN
10	CD
(	(
6	CD
)	)
plaque-forming	JJ
units	NNS
(	(
pfu	NN
)	)
of	IN
AVTGFbeta1	NN
,	,
provide	VBP
essentially	RB
a	DT
`	``
no-effect	NN
'	''
dose	NN
,	,
but	CC
even	RB
this	DT
amount	NN
of	IN
TGF-beta1	NN
causes	VBZ
a	DT
significant	JJ
increase	NN
in	IN
whole-lung	JJ
collagen	NN
by	IN
day	NN
28	CD
after	IN
treatment	NN
.	.

In	IN
contrast	NN
,	,
10	CD
(	(
8	CD
)	)
and	CC
10	CD
(	(
9	CD
)	)
pfu	NN
cause	NN
severe	JJ
IPF	NN
in	IN
4	CD
days	NNS
,	,
whereas	IN
10	CD
(	(
7	CD
)	)
and	CC
5	CD
x	CC
10	CD
(	(
7	CD
)	)
are	VBP
intermediate	JJ
for	IN
all	DT
parameters	NNS
studied	VBN
,	,
i.e.	FW
TGF-beta	NN
protein	NN
,	,
inflammatory	JJ
cells	NNS
,	,
cell	NN
proliferation	NN
,	,
pro-alpha	NN
1	CD
(	(
I	PRP
)	)
collagen	NN
gene	NN
expression	NN
and	CC
whole-lung	JJ
collagen	NN
accumulation	NN
,	,
and	CC
expression	NN
of	IN
growth	NN
factors	NNS
such	JJ
as	IN
TGF-beta1	NN
,	,
TNF-alpha	NN
and	CC
PDGF-A-and	NN
--	:
B.	NNP
Interestingly	RB
enough	RB
,	,
TGF-beta1	NN
,	,
as	IN
a	DT
potent	JJ
blocker	NN
of	IN
epithelial	JJ
cell	NN
proliferation	NN
,	,
appears	VBZ
to	TO
suppress	VB
airway	NN
epithelial	JJ
cell	NN
growth	NN
that	WDT
would	MD
be	VB
expected	VBN
during	IN
the	DT
inflammatory	JJ
phase	NN
of	IN
IPF	NN
.	.

Thus	RB
,	,
this	DT
model	NN
system	NN
helps	VBZ
us	PRP
to	TO
understand	VB
some	DT
quantitative	JJ
aspects	NNS
of	IN
TGF-beta1	NN
biological	JJ
activity	NN
and	CC
allows	VBZ
us	PRP
to	TO
manipulate	VB
this	DT
potent	JJ
factor	NN
as	IN
a	DT
mediator	NN
of	IN
interstitial	JJ
fibrogenesis	NN
.	.

